Skip to main content
. 2020 Dec 13;14(2):100961. doi: 10.1016/j.tranon.2020.100961

Fig. 4.

Fig. 4

Metabolite of BEBT-109 (M5) inhibits cell growths and EGFR phosphorylation against EGFR-mutant NSCLC. A, Proposed BEBT-109 metabolic pathways show the formation of metabolites (M1-M9). B-D, Cell growth inhibition of BEBT-109 metabolic substance M5 in cell lines expressing EGFR TKI-sensitive mutants (n = 3) (B), EGFR TKI-resistant mutants (n = 3) (C) and wild type EGFR (n = 2) (D). E and F, Effects of EGFR phosphorylation and its downstream signaling pathways by BEBT-109 metabolic substances (M5) in cells expressing EGFR TKI-sensitive (E) and TKI-resistant (F) mutants.